Chemomab changes CEOs, sus­pends mid-stage tri­al; Ex-FDA vac­cine of­fi­cial lends more help to Mesoblast

→ There’s a shake­up at the top of Chemomab Ther­a­peu­tics as the Is­raeli biotech halts the start of a Phase II study to save cash. In moves that took ef­fect on June 1, co-founder and CSO Adi Mor is run­ning it back as CEO, re­plac­ing Dale Pfost, and VP of fi­nance Si­gal Fat­tal has been pro­mot­ed to CFO. Both Pfost and ex-fi­nance chief Don Mar­vin were col­leagues at Or­chid Bio­sciences and Lo­do Ther­a­peu­tics. To round out these changes, Eli­raz Ven­tures gen­er­al part­ner and for­mer Or­biMed Is­rael ven­ture part­ner Nis­sim Darvish has suc­ceed­ed Pfost as chair­man.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER